ScholarIQanswers from OpenAlex
Cutaneous lymphoproliferative disorders research
TopicLeading institutions, researchers & key papers
Cutaneous lymphoproliferative disorders research is a topic indexed in ScholarIQ from OpenAlex.
What is known about Cutaneous lymphoproliferative disorders research?
ScholarIQrecord summary
This cluster of papers focuses on the classification, staging, treatment, and prognosis of cutaneous lymphomas, with a specific emphasis on mycosis fungoides and Sézary syndrome. It includes discussions on the WHO-EORTC classification, survival outcomes, prognostic factors, and various treatment options such as bexarotene and denileukin diftitox. The cluster also addresses the incidence patterns, genomic landscape, and molecular profiling of cutaneous T-cell lymphomas.
How many works does Cutaneous lymphoproliferative disorders research have?
ScholarIQindexed works
Cutaneous lymphoproliferative disorders research has 102 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Cutaneous lymphoproliferative disorders research?
ScholarIQopenalex
The OpenAlex for Cutaneous lymphoproliferative disorders research is on the source record.
What are the most-cited papers on Cutaneous lymphoproliferative disorders research?
ScholarIQmost cited works
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Elise A. Olsen, Eric C. Vonderheid, Nicola Pimpinelli, Rein Willemze, Youn Kim, Robert Knobler, Herschel Zackheim, Madeleine Duvic, Teresa Estrach, Stanford Lamberg, Gary S. Wood, Reinhard Dummer, Annamari Ranki, Günter Burg, Peter Heald, Mark R. Pittelkow, M.G. Bernengo, Wolfram Sterry, L. Laroche, Franz Trautinger, Sean Whittaker
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen, Sean Whittaker, Youn H. Kim, Madeleine Duvic, H. Miles Prince, Stuart R. Lessin, Gary S. Wood, Rein Willemze, Marie‐France Demierre, Nicola Pimpinelli, Maria Grazia Bernengo, Pablo L. Ortiz‐Romero, M. Bagot, Teresa Estrach, Joan Guitart, Robert Knobler, José Antônio Sanches, Keiji Iwatsuki, Makoto Sugaya, Reinhard Dummer, Mark R. Pittelkow, Richard T. Hoppe, Sareeta Parker, Larisa J. Geskin, Lauren Pinter‐Brown, Michael Girardi, Günter Burg, Annamari Ranki, Maarten H. Vermeer, Sarah McCue Horwitz, Peter Heald, Steven T. Rosen, Lorenzo Cerroni, Brigette Dréno, Eric C. Vonderheid
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura
Defining early mycosis fungoides
Nicola Pimpinelli, Elise A. Olsen, Marco Santucci, Eric C. Vonderheid, A Haeffner, Seth R. Stevens, Guenter Burg, Lorenzo Cerroni, Brigitte Dréno, Earl J. Glusac, Joan Guitart, Peter Heald, Werner Kempf, Robert Knobler, Stuart R. Lessin, Christian A. Sander, Bruce S. Smoller, Gladys H. Telang, Sean Whittaker, Keiji Iwatsuki, Erik Obitz, Masahiro Takigawa, Maria L. Turner, Gary S. Wood
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)
Youn H. Kim, Rein Willemze, Nicola Pimpinelli, Sean Whittaker, Elise A. Olsen, Annamari Ranki, Reinhard Dummer, Richard T. Hoppe
Where is Cutaneous lymphoproliferative disorders research research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Cutaneous lymphoproliferative disorders research is open access?
ScholarIQopen access share
80%OPEN ACCESS